Clinical and genomic analyses of neuroendocrine neoplasms of the breast

Wei, Yani; Ke, Xue-Xuan; Yu, Jing; Jing, Qiuyang; Bu, Hong; Zeng, Xiangfei; Wei, Bing

doi:10.1038/s41379-021-00965-w

Cited by 11 publications

(4 citation statements)

References 50 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…[18][19][20][21][22][23] In breast cancers, p53 mutation is associated with more aggressive disease and worse overall survival. 20,24 In our study, NECs had signi cantly higher frequency of p53 mutation than NETs or IBC-NST-Nes (60% vs 0% or 11%). Our ndings are consistent with recent studies which showed more frequent p53 mutation in NECs of the breast.…”

Section: Discussionmentioning

confidence: 49%

Comprehensive analysis of clinicopathologic features and p53 mutation in neuroendocrine neoplasms of the breast: experience from a large academic center

Shafi

Hu²,

Parwani³

et al. 2022

Breast Cancer Res Treat

View full text Add to dashboard Cite

Purpose The recent WHO classi cation of breast cancer (2019) categorizes breast carcinoma with neuroendocrine (NE) differentiation into three morphologically distinct subtypes: well-differentiated neuroendocrine tumor (NET), poorly differentiated neuroendocrine carcinoma (NEC), and invasive breast carcinoma, no special type with neuroendocrine differentiation (IBC-NST-NE). Data regarding the prognostic signi cance of neuroendocrine differentiation are con icting and an association, if any, between p53 mutation and neuroendocrine differentiation is largely unknown.Methods We examined p53 expression and other clinicopathologic characteristics in three types of invasive breast carcinoma with NE differentiation in a cohort of sixty-three patients, including 45 IBC-NST with NE differentiation, 10 NETs and 8 NECs.Results No signi cant difference of clinicopathologic feature was observed between IBC-NST with NE differentiation and NET, but NECs showed signi cantly lower expressions of hormone receptors, more mutated p53 and higher frequency of distant metastases than IBC-NST with NE differentiation and NETs.Conclusions NECs of the breast are genetically and clinically different from IBC-NST-NEs and NETs of the breast.

show abstract

Section: Discussionmentioning

confidence: 49%

Comprehensive analysis of clinicopathologic features and p53 mutation in neuroendocrine neoplasms of the breast: experience from a large academic center

Shafi

Hu²,

Parwani³

et al. 2022

Breast Cancer Res Treat

View full text Add to dashboard Cite

show abstract

“…MAP3K4 is a specific gene related to tumorigenesis. Its mutation, regulating filamin expression and neuronal migration [ 7 ], was detected in breast neuroendocrine neoplasms (NENs), a peculiar histologic subtype [ 93 ]. Genome-wide sequencing shows that MAP3K4 and its mutations also frequently appear in several kinds of tumor tissues, such as serous endometrial tumor [ 94 ], wilms tumor [ 95 ], EBV-positive gastric tumor [ 96 ], pancreatic cancer [ 97 ], and family lung cancer [ 98 ].…”

Section: The Complex Function Of Map3k4 Concerning Tumormentioning

confidence: 99%

MAP3K4 kinase action and dual role in cancer

Huang,

Wang,

Zhang

et al. 2024

Discov Onc

View full text Add to dashboard Cite

It is commonly known that the MAPK pathway is involved in translating environmental inputs, regulating downstream reactions, and maintaining the intrinsic dynamic balance. Numerous essential elements and regulatory processes are included in this pathway, which are essential to its functionality. Among these, MAP3K4, a member of the serine/threonine kinases family, plays vital roles throughout the organism's life cycle, including the regulation of apoptosis and autophagy. Moreover, MAP3K4 can interact with key partners like GADD45, which affects organism's growth and development. Notably, MAP3K4 functions as both a tumor promotor and suppressor, being activated by a variety of factors and triggering diverse downstream pathways that differently influence cancer progression. The aim of this study is to provide a brief overview of physiological functions of MAP3K4 and shed light on its contradictory roles in tumorigenesis.

show abstract

“…Numerous papers have been published through the years describing NE breast tumours (Table 1). 13,20,30,32–69 There is variation in how these tumours were defined and diagnosed, with some equating invasive breast carcinoma with NE differentiation as NEN/NET while others conform to the recently endorsed terminology for NEN, 9 with only rare reports of ‘carcinoids’. NECs form a significant proportion of these publications.…”

Section: Not Against (Puay Hoon Tan)mentioning

confidence: 99%

Head to head: do neuroendocrine tumours in the breast truly exist?

Rakha

Tan

2022

Histopathology

View full text Add to dashboard Cite

Breast cancer (BC) is a heterogeneous disease with a spectrum of morphological features. Concepts of histogenesis and differentiation in BC remain controversial. Recent evidence supports differentiation rather than histogenesis as the underlying mechanism for the myriad morphological appearances of BC. Prognosis and response to therapy are determined by a combination of factors, including tumour grade, stage and receptor status, whereas tumour histological types play an independent role in only limited examples. Neuroendocrine tumours (NETs) comprise one of the most debated entities in the breast since their first description. Apart from the rare small‐cell NE carcinoma (NEC), which has well‐characterized features similar to their counterparts in other organs, the true existence, diagnostic criteria and clinical significance of NE neoplasms (NENs) in the breast are shrouded in controversy. At the core of this discussion is whether normal NE cells exist in the breast, and if breast NETs have distinct morphology and clinical behaviour. When NETs are encountered in the breast, metastatic origin has to be excluded. The more frequent situation in which NE differentiation is observed in breast cancers is in the context of recognizable, morphologically well‐described special‐type neoplasms such as the hypercellular mucinous carcinoma and solid papillary carcinoma. In this review, arguments for and against maintaining the category of NENs in the breast are articulated in relation to existing literature on this group of unusual tumours.

show abstract

Clinical and genomic analyses of neuroendocrine neoplasms of the breast

Cited by 11 publications

References 50 publications

Comprehensive analysis of clinicopathologic features and p53 mutation in neuroendocrine neoplasms of the breast: experience from a large academic center

Comprehensive analysis of clinicopathologic features and p53 mutation in neuroendocrine neoplasms of the breast: experience from a large academic center

MAP3K4 kinase action and dual role in cancer

Head to head: do neuroendocrine tumours in the breast truly exist?

Contact Info

Product

Resources

About